Characterization of a Set of HIV-1 Protease Inhibitors Using Binding Kinetics Data from a Biosensor-Based Screen

The interaction between 290 structurally diverse human immunodeficiency virus type 1 (HIV-1) protease inhibitors and the immobilized enzyme was analyzed with an optical biosensor. Although only a single concentration of inhibitor was used, information about the kinetics of the interaction could be obtained by extracting binding signals at discrete time points. The statistical correlation between the biosensor binding data, inhibition of enzyme activity (K;), and viral replication (EC50) revealed that the association and dissociation rates for the interaction could be resolved and that they were characteristic for the compounds. The most potent inhibitors, with respect to K; and EC50 values, including the clinically used drugs, all exhibited fast association and slow dissociation rates. Selective or partially selective binders for HIV-1 protease could be distinguished from compounds that showed a general protein-binding tendency by using three reference target proteins. This biosensor-based direct binding assay revealed a capacity to efficiently provide high-resolution information on the interaction kinetics and specificity of the interaction of a set of compounds with several targets simultaneously.

[1]  M. Hämäläinen,et al.  Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology. , 2000, Analytical biochemistry.

[2]  L. Vrang,et al.  Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. , 1999, Journal of medicinal chemistry.

[3]  M. Hämäläinen,et al.  Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. , 1998, Analytical Biochemistry.

[4]  B. Samuelsson,et al.  Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. , 1998, Journal of medicinal chemistry.

[5]  B. Samuelsson,et al.  HIV-1 protease inhibitors based on acyclic carbohydrates , 1998 .

[6]  J. Hulten,et al.  Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs , 1997, Antimicrobial agents and chemotherapy.

[7]  J. Condra,et al.  Clinically effective HIV-1 protease inhibitors , 1997 .

[8]  D. Nöteberg,et al.  Synthesis of enantiomerically pure cis and trans 2-aminocyclopentanecarboxylic acids. Use of proline replacements in potential HIV-protease inhibitors , 1997 .

[9]  B. Samuelsson,et al.  A convenient synthesis of 1-(S)-[1′-(S)-(t-butyloxycarbonylamino)-2′-phenylethyl]oxirane. A useful building block in the synthesis of HIV protease inhibitors , 1997 .

[10]  J. Åqvist,et al.  Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. , 1997, Journal of medicinal chemistry.

[11]  Larry Wall,et al.  Programming Perl (2nd ed.) , 1996 .

[12]  B. Samuelsson,et al.  Synthesis of C-2 symmetric potential inhibitors of HIV-1 protease from D-mannitol , 1996 .

[13]  S. Hirono,et al.  Comparison of Reliability of log P Values for Drugs Calculated by Several Methods , 1994 .

[14]  R. Karlsson,et al.  Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. , 1992, Journal of chromatography.

[15]  S. Hirono,et al.  Simple Method of Calculating Octanol/Water Partition Coefficient. , 1992 .

[16]  Larry Wall,et al.  Programming Perl , 1991 .